`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`MICROSOFT CORPORATION and HP INC.,
`
`Petitioners
`
` v.
`
` SYNKLOUD TECHNOLOGIES, LLC,
`
`Patent Owner
`
` _________
`
`Case IPR2020-01235
`
`U.S. Patent 10,015,254
`
`
`
` PATENT OWNER’S MOTION TO SEAL
`37 C.F.R. §§42.54, 42.55
`
`
`
`
`
`Patent Owner Synkloud Technologies, LLC (“PO” herein) moves to
`
`submit confidential information as evidence in support of its position in the
`
`above-captioned matter, and accordingly moves that Exhibits 2029, 2030, and
`
`2039 submitted contemporaneously herewith, be accepted but not made public
`
`and maintained confidential to a Modified Protective Order submitted herewith
`
`as Exhibit 2036. In so moving, PO is guided by this Board’s Decision in
`
`IPR2017-01053, Paper No. 27, and decisions cited therein, including IPR2012-
`
`00001, Paper No. 34.
`
`PO, as an element of its position that the claims challenged in the above-
`
`captioned IPR are not obvious over prior art cited, wishes to submit two licenses
`
`extended under the patent at issue, U.S. Patent No. 10,015,254 (“the ‘254
`
`patent”) along with an associated claim chart as secondary indicia of non-
`
`obviousness pursuant to well-established caselaw. See, e.g., Rothman v. Target
`
`Corp. 556 F. 3d 1310, 1321 (Fed. Cir. 2009). The public is not denied essential
`
`information by sealing Exhibits 2029, 2030, and 2039. The Exhibits are two
`
`licenses between the owner of the ‘254 Patent and two recognized corporations,
`
`in consideration of payment of fees, along with an associated claim chart. No
`
`other issues, such as sales, conditions, promotions or other issues are set forth in
`
`or raised by the licenses, and thus, questions such as nexus and the like are not
`
`raised. PO does not rely on the identity of the Licensees, other than to note they
`
`are recognized major corporations in the computer technology field. PO does not
`
`rely on the specific terms of the licenses, other than to note the licenses extended
`
`
`
`are in consideration of payment of money, and no other consideration flows
`
`between the parties.
`
`By its terms, further information with respect to the licenses and
`
`associated claim chart is confined to outside counsel only. To that end, PO has
`
`fashioned a Protective Order premised on the Board’s default protective order in
`
`the practice guide, but altered to limit the confidential information submitted to
`
`the specific counsel appearing for Petitioners in this matter. Submission of this
`
`information, which Court’s have often found of value in considering questions
`
`of obviousness, without seal or protection, would potentially vitiate the licenses
`
`as a possible breach thereof and/or expose PO to liability.
`
`Undersigned counsel has conferred with opposing counsel. Opposing
`
`counsel agreed to the Modified Protective Order that is Exhibit 2036.
`
`Accordingly, PO respectfully requests Exhibits 2029, 2030, and 2039 be
`
`held confidential to the Board provisionally, pending grant of this Motion or
`
`expungement if this Motion is denied.
`
`Respectfully, PO submits it has met the Board’s standard for submission
`
`under seal, Argentum Pharmaceuticals LLC v. Alcon Research, IPR 2017-
`
`01053, Paper 27 (January 19, 2018) at p. 4. 1) The confidential information, two
`
`patent licenses, is truly confidential – it is confidential by its terms. 2) Concrete
`
`harm would result upon public disclosure of Exhibits 2029 or 2039, it would
`
`constitute a potential breach of the very license at issue. 3) There exists a
`
`genuine need to rely in the trial on the specific information sought to be sealed.
`
`
`
`It is PO’s strong evidence of a judicially recognized indication of non-
`
`obviousness – a patent license. 4) On balance, the interest in maintaining
`
`confidentiality as to this one exhibit outweighs the strong public interest in
`
`having an open record.
`
`On this basis, and in light of the proposed Modified Protective Order that
`
`is Exhibit 2036, PO respectfully requests grant of this Motion and acceptance of
`
`Exhibits 2029, 2030, and 2039 under seal.
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`/Gregory J. Gonsalves/
`Dr. Gregory J. Gonsalves
`Reg. No. 43,639
`Capitol IP Law Group, PLLC
`1918 18th St, Unit 4, NW
`Washington, DC 20009
`Phone: 571-419-7252
`Email:
`gonsalves@capitoliplaw.com
`
`
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. 42.6(e) and by the agreement of counsel for Petitioner, I
`
`certify that on April 19, 2021, I served a complete electronic copy of the Motion on
`
`the Petitioner’s lead and backup counsel at the following email addresses:
`
`Lead Counsel
`
`James L. Day (Reg. No. 72,681)
`Farella Braun + Martel LLP
`235 Montgomery Street, 17th Floor
`San Francisco, California, 94104.
`jday@fbm.com
`
`Backup Counsel
`
`Winston Liaw (Reg. No. 78,766)
`Daniel Callaway (Reg. No. 74,267)
`Farella Braun + Martel LLP
`235 Montgomery Street, 17th Floor
`San Francisco, California, 94104.
`wliaw@fbm.com
`dcallaway@fbm.com
`calendar@fbm.com
`
`
`/Gregory J. Gonsalves/
`Dr. Gregory J. Gonsalves
`Reg. No. 43,639
`Capitol IP Law Group, PLLC
`1918 18th St, Unit 4, NW
`Washington, DC 20009
`Phone: 571-419-7252
`Email: gonsalves@capitoliplaw.com
`
`
`
`